Xu et al., in their study, highlighted that the use of bevacizumab, a VEGF-A inhibitor, in the short term would determine a reduction in tumor growth and an adaptive effect of metastatic cells known as metastatic conditioning [62]. The gene discussed is VEGFA; the disease is neoplasm.